XERS Key Statistics, Chart & Performance
The current stock price of XERS is 7.44 USD. In the past month the price increased by 2.2%. In the past year, price increased by 115.65%.
XERS Technical Analysis
ChartMill assigns a technical rating of 6 / 10 to XERS. When comparing the yearly performance of all stocks, XERS is one of the better performing stocks in the market, outperforming 92.4% of all stocks.
XERS Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to XERS. Both the profitability and financial health of XERS have multiple concerns.
XERS Financial Highlights
Over the last trailing twelve months XERS reported a non-GAAP Earnings per Share(EPS) of -0.1. The EPS increased by 77.78% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -4.22% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
XERS Forecast & Estimates
13 analysts have analysed XERS and the average price target is 11.37 USD. This implies a price increase of 52.77% is expected in the next year compared to the current price of 7.44.
For the next year, analysts expect an EPS growth of 88.37% and a revenue growth 43.35% for XERS
XERS Ownership
About XERS
Company Profile
Xeris Biopharma Holdings, Inc. is a biopharmaceutical company, which engages in developing and commercializing products across a range of therapies. The company is headquartered in Chicago, Illinois and currently employs 394 full-time employees. The company went IPO on 2018-06-21. The company has three commercially available products: Recorlev, Gvoke, and Keveyis. Recorlev is for the treatment of endogenous Cushing’s syndrome. Gvoke is a ready-to-use liquid glucagon for the treatment of severe hypoglycemia. Keveyis is a therapy for primary periodic paralysis. The company also has a pipeline of development programs led by XP-8121, a phase III-ready, once-weekly subcutaneous injection for hypothyroidism. The company is pursuing formulation and development partnerships to apply its XeriSol and XeriJect formulation technologies to enhance the drug delivery and clinical profile of other companies’ proprietary drugs and biologics. Recorlev is a cortisol synthesis inhibitor approved for the treatment of endogenous hypercortisolemia in adults with Cushing's syndrome for whom surgery is not an option or has not been curative.
Company Info
XERIS BIOPHARMA HOLDINGS INC
1375 West Fulton Street, Suite 1300
Chicago ILLINOIS 60601 US
CEO: Paul R. Edick
Employees: 394
Phone: 18444455704
XERIS BIOPHARMA HOLDINGS INC / XERS FAQ
Can you describe the business of XERIS BIOPHARMA HOLDINGS INC?
Xeris Biopharma Holdings, Inc. is a biopharmaceutical company, which engages in developing and commercializing products across a range of therapies. The company is headquartered in Chicago, Illinois and currently employs 394 full-time employees. The company went IPO on 2018-06-21. The company has three commercially available products: Recorlev, Gvoke, and Keveyis. Recorlev is for the treatment of endogenous Cushing’s syndrome. Gvoke is a ready-to-use liquid glucagon for the treatment of severe hypoglycemia. Keveyis is a therapy for primary periodic paralysis. The company also has a pipeline of development programs led by XP-8121, a phase III-ready, once-weekly subcutaneous injection for hypothyroidism. The company is pursuing formulation and development partnerships to apply its XeriSol and XeriJect formulation technologies to enhance the drug delivery and clinical profile of other companies’ proprietary drugs and biologics. Recorlev is a cortisol synthesis inhibitor approved for the treatment of endogenous hypercortisolemia in adults with Cushing's syndrome for whom surgery is not an option or has not been curative.
Can you provide the latest stock price for XERIS BIOPHARMA HOLDINGS INC?
The current stock price of XERS is 7.44 USD. The price decreased by -2.23% in the last trading session.
Does XERIS BIOPHARMA HOLDINGS INC pay dividends?
XERS does not pay a dividend.
How is the ChartMill rating for XERIS BIOPHARMA HOLDINGS INC?
XERS has a ChartMill Technical rating of 6 out of 10 and a ChartMill Fundamental rating of 4 out of 10.
What is the expected growth for XERS stock?
The Revenue of XERIS BIOPHARMA HOLDINGS INC (XERS) is expected to grow by 43.35% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
What is the ownership structure of XERIS BIOPHARMA HOLDINGS INC (XERS)?
You can find the ownership structure of XERIS BIOPHARMA HOLDINGS INC (XERS) on the Ownership tab.
What is the Short Interest ratio of XERIS BIOPHARMA HOLDINGS INC (XERS) stock?
The outstanding short interest for XERIS BIOPHARMA HOLDINGS INC (XERS) is 10.37% of its float.